会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • METHODS AND COMPOSITIONS FOR DIAGNOSING MEDICAL CONDITIONS
    • 用于诊断医学条件的方法和组合物
    • WO2012007531A2
    • 2012-01-19
    • PCT/EP2011/062006
    • 2011-07-13
    • MADEO, FrankEISENBERG, TobiasPIEBER, ThomasMAGNES, ChristophSINNER, FrankWINDERICKX, JorisVAN DEN BERGHE, GretGUNST, Jan
    • MADEO, FrankEISENBERG, TobiasPIEBER, ThomasMAGNES, ChristophSINNER, FrankWINDERICKX, JorisVAN DEN BERGHE, GretGUNST, Jan
    • G01N33/53
    • G01N33/5308G01N2800/042
    • The present invention relates to a method for diagnosing and/or monitoring in a subject a non-infectious medical condition or a predisposition to develop a non-infectious medical condition, comprising detecting and/or analyzing in a test sample derived from the subject one or more polyamines or one or more salts or derivatives thereof, wherein the presence of any one of the polyamines or the salts or derivatives thereof in the test sample is indicative of the medical condition or a predisposition to develop the medical condition. In particular embodiments, the method further comprises quantifying the levels of the one or more polyamines or the one or more salts or derivatives thereof in the test sample, wherein an altered level of any one the polyamines or the salts or derivatives thereof in the test sample as compared to a reference is indicative of the non-infectious medical condition or a predisposition to develop such condition. The present invention is also directed to a kit-of-parts for diagnosing and/or monitoring in a subject a non-infectious medical condition or a predisposition to develop such condition, comprising means for detecting and/or analyzing one or more polyamines or one or more salts or derivatives thereof, as defined herein, as well as to the use of one or more polyamines or one or more salts or derivatives thereof, as defined herein, as a panel of molecular markers for diagnosing a non-infectious medical condition or a predisposition to develop such condition.
    • 本发明涉及用于诊断和/或监测受试者非传染性医学状况或倾向于发展非感染性医学病症的方法,包括在来自受试者的测试样品中检测和/或分析样品,或 更多的多胺或其一种或多种盐或其衍生物,其中在测试样品中多胺或其盐或衍生物中的任何一种的存在表示医学状况或发展医学病症的倾向。 在具体实施方案中,该方法还包括定量测试样品中一种或多种多胺或其一种或多种盐或衍生物的含量,其中测试样品中多胺或其盐或衍生物中任何一种的改变水平 与参考文献相比,表示非传染性医学状况或发展这种病症的倾向。 本发明还涉及用于诊断和/或监测受试者的非感染性医学病症或倾向于开发这种病症的试剂盒,其包括用于检测和/或分析一种或多种多胺或一种或多种多胺 或其更多的盐或衍生物,以及本文定义的一种或多种多胺或其一种或多种盐或其衍生物作为诊断非感染性医学病症的分子标记物的一组或 发展这种状况的倾向。
    • 5. 发明申请
    • ALPHA SYNUCLEIN TOXICITY
    • ALPHA SYNUCLEIN毒性
    • WO2009021295A2
    • 2009-02-19
    • PCT/BE2008/000062
    • 2008-08-07
    • KATHOLIEKE UNIVERSITEIT LEUVENUNIVERSITY OF GRAZBAEKELANDT, VeerleBUETTNER, SabrinaMADEO, FrankWINDERICKX, Joris
    • BAEKELANDT, VeerleBUETTNER, SabrinaMADEO, FrankWINDERICKX, Joris
    • C07K16/00
    • A61K39/3955A61K31/713A61K38/005A61K2039/505C07K16/40C12N15/1137C12N2310/14
    • Present inventions demonstrates that alpha synculein toxicity such as α-synuclein mediated cell death, alpha synuclein induced reactive oxygen species (ROS) in a cell requires the proapoptotic endonuclease G and that the deletion of the endonuclease G or suppressing of the endonuclease G apoptotic pathway attenuates or counteracts such alpha synuclein toxicity. The present invention compositions and methods for inhibition of α-synuclein toxicity. The inhibiting α-synuclein toxicity can be used in methods of treatment of synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), and multiple system atrophy (MSA) and the manufacture of medicaments for such treatment. In particular The subject matter provided in herein relates to a pharmaceutical compositions containing inhibitors of endonuclease G, and their use in the treatment of synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies, pure autonomic failure, and multiple system atrophy and the manufacture of medicaments for such treatment. Furthermore the present invention relates to a method for the identification of compounds attenuating the synuclein toxicity, said method comprising evaluating the inhibitory action of said compound on the endonuclease G dependent apoptosis.
    • 本发明证明α-突触素毒性如α-突触核蛋白介导的细胞死亡,α突触核蛋白在细胞中诱导活性氧(ROS)需要促凋亡内切酶G,并且内切核酸酶G的缺失或内切核酸酶G凋亡通路的抑制减弱 或抵抗这种α突触核蛋白毒性。 本发明的组合物和抑制α-突触核蛋白毒性的方法。 抑制性α-突触核蛋白毒性可用于治疗突触核蛋白病,如帕金森病(PD),路易体痴呆(DLB),纯自主神经功能衰竭(PAF)和多系统萎缩(MSA) 药物用于治疗。 特别地,本文提供的主题涉及含有内切核酸酶G抑制剂的药物组合物及其在治疗突触核蛋白病(例如帕金森病,路易体痴呆,纯粹的自主神经衰竭和多系统萎缩)中的用途,以及制造 药物用于治疗。 此外,本发明涉及鉴定减毒突触核蛋白毒性的化合物的方法,所述方法包括评价所述化合物对核酸内切酶G依赖性凋亡的抑制作用。